115 related articles for article (PubMed ID: 8186870)
1. Combined hyperthermia and immunotherapy treatment of multiple pulmonary metastases in mice.
Strauch ED; Fabian DF; Turner J; Lefor AT
Surg Oncol; 1994 Feb; 3(1):45-52. PubMed ID: 8186870
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
4. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
5. Indomethacin-enhanced immunotherapy of pulmonary metastases using IL-2 and IFN-alpha.
Kim B; Warnaka P
Surgery; 1989 Aug; 106(2):248-55; discussion 255-6. PubMed ID: 2788316
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.
Mulé JJ; Shu S; Schwarz SL; Rosenberg SA
Science; 1984 Sep; 225(4669):1487-9. PubMed ID: 6332379
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy and whole-body hyperthermia as combined modality treatment of a subcutaneous murine sarcoma.
Geehan DM; Fabian DF; Lefor AT
J Surg Oncol; 1993 Jul; 53(3):180-3. PubMed ID: 8331940
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
9. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
Mulé JJ; Shu S; Rosenberg SA
J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy of intracerebral metastases in mice.
McCutcheon IE; Baranco RA; Katz DA; Saris SC
J Neurosurg; 1990 Jan; 72(1):102-9. PubMed ID: 2294169
[TBL] [Abstract][Full Text] [Related]
11. Enhanced survival of IFN-alpha augmented IL-2 therapy of pulmonary metastases: efficacy comparable to interleukin-2 and lymphokine activated killer cells.
Kim B; Warnaka P
J Surg Res; 1991 Jan; 50(1):40-6. PubMed ID: 1987429
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
Rosenberg SA; Mulé JJ
Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
[TBL] [Abstract][Full Text] [Related]
13. Lymphocyte migration to tumors after hyperthermia and immunotherapy.
Midis GP; Fabian DF; Lefor AT
J Surg Res; 1992 May; 52(5):530-6. PubMed ID: 1619922
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor.
Tjota A; Zhang YQ; Piedmonte MR; Lee CL
J Urol; 1991 Jul; 146(1):177-83. PubMed ID: 2056587
[TBL] [Abstract][Full Text] [Related]
15. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
16. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
[TBL] [Abstract][Full Text] [Related]
17. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
Kedar E; Ben-Aziz R; Shiloni E
Isr J Med Sci; 1988; 24(9-10):494-504. PubMed ID: 3264551
[TBL] [Abstract][Full Text] [Related]
18. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
Rosenberg SA; Mulé JJ; Spiess PJ; Reichert CM; Schwarz SL
J Exp Med; 1985 May; 161(5):1169-88. PubMed ID: 3886826
[TBL] [Abstract][Full Text] [Related]
19. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
Lee K; O'Donnell RW; Cockett AT
J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
[TBL] [Abstract][Full Text] [Related]
20. Effect of thermoimmunotherapy with OK-432 on the development of spontaneous lung metastases in mice.
Taradi SK; Taradi M; Urano M
Int J Hyperthermia; 1992; 8(2):221-6. PubMed ID: 1573311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
